Continuous Manufacturing For Small Molecule APIs Market Size, Share & Trends Analysis Report By Equipment (Reactors, Crystallizers, Filtration Systems), By Unit Operation, By Type, By End Use, By Region, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within Immediate
Continuous Manufacturing For Small Molecule APIs Market Growth & Trends
The global continuous manufacturing for small molecule APIs market size is anticipated treach USD 671.52 million by 2030, growing at a CAGR of 10.42% from 2024 t2030, according ta report by Grand View Research, Inc. This robust expansion can be attributed tseveral key drivers that reflect current industry trends, advancements in technology, and changing regulatory landscapes. Continuous manufacturing processes offer significant advantages over traditional batch processing, including increased efficiency, reduced production costs, and improved product quality. The United States Food and Drug Administration (FDA) has actively promoted continuous manufacturing technologies, recognizing their potential tstreamline the drug production process and enhance the overall quality of pharmaceutical products. For instance, the FDA’s “Pharmaceutical Quality for the 21st Century” initiative highlights continuous manufacturing as a key focus area, encouraging companies tadopt these innovative approaches tensure better control over production variables.
Recent technological advancements further propel the continuous manufacturing market. Innovations in process analytical technology (PAT) enable real-time monitoring of production processes, ensuring consistent quality and compliance with regulatory standards. For instance, in July 2024, GEA introduced new continuous processing technologies designed tenhance flexibility and efficiency in pharmaceutical manufacturing. At ACHEMA 2024, GEA showcased its collaboration with Hovione, emphasizing the ConsiGma CDC flex system. This system supports both continuous and batch processes with varied throughput, improving production quality and sustainability. Their partnership aims tsimplify operations and make continuous manufacturing more accessible across the industry.These technologies not only increase efficiency but alssignificantly shorten time-to-market for new drugs, an essential factor in an increasingly competitive pharmaceutical industry.
Government initiatives and support alsplay a crucial role in the growth of the continuous manufacturing market. Various countries are recognizing the need for modernization in pharmaceutical manufacturing tenhance competitiveness and improve public health outcomes. For example, the U.S. government has introduced programs aimed at facilitating the adoption of continuous manufacturing technologies, providing funding and resources tsupport innovation within the industry. Similarly, the European Medicines Agency (EMA) has been encouraging the use of continuous processes, promoting guidelines that facilitate the implementation of these technologies within Europe’s pharmaceutical sector.
Continuous Manufacturing For Small Molecule APIs Market Report Highlights
Continuous Manufacturing For Small Molecule APIs Market Growth & Trends
The global continuous manufacturing for small molecule APIs market size is anticipated treach USD 671.52 million by 2030, growing at a CAGR of 10.42% from 2024 t2030, according ta report by Grand View Research, Inc. This robust expansion can be attributed tseveral key drivers that reflect current industry trends, advancements in technology, and changing regulatory landscapes. Continuous manufacturing processes offer significant advantages over traditional batch processing, including increased efficiency, reduced production costs, and improved product quality. The United States Food and Drug Administration (FDA) has actively promoted continuous manufacturing technologies, recognizing their potential tstreamline the drug production process and enhance the overall quality of pharmaceutical products. For instance, the FDA’s “Pharmaceutical Quality for the 21st Century” initiative highlights continuous manufacturing as a key focus area, encouraging companies tadopt these innovative approaches tensure better control over production variables.
Recent technological advancements further propel the continuous manufacturing market. Innovations in process analytical technology (PAT) enable real-time monitoring of production processes, ensuring consistent quality and compliance with regulatory standards. For instance, in July 2024, GEA introduced new continuous processing technologies designed tenhance flexibility and efficiency in pharmaceutical manufacturing. At ACHEMA 2024, GEA showcased its collaboration with Hovione, emphasizing the ConsiGma CDC flex system. This system supports both continuous and batch processes with varied throughput, improving production quality and sustainability. Their partnership aims tsimplify operations and make continuous manufacturing more accessible across the industry.These technologies not only increase efficiency but alssignificantly shorten time-to-market for new drugs, an essential factor in an increasingly competitive pharmaceutical industry.
Government initiatives and support alsplay a crucial role in the growth of the continuous manufacturing market. Various countries are recognizing the need for modernization in pharmaceutical manufacturing tenhance competitiveness and improve public health outcomes. For example, the U.S. government has introduced programs aimed at facilitating the adoption of continuous manufacturing technologies, providing funding and resources tsupport innovation within the industry. Similarly, the European Medicines Agency (EMA) has been encouraging the use of continuous processes, promoting guidelines that facilitate the implementation of these technologies within Europe’s pharmaceutical sector.
Continuous Manufacturing For Small Molecule APIs Market Report Highlights
- Based on equipment, reactors dominated the market with a substantial share of 35.2% in 2023 and are expected tgrow at the fastest CAGR of 11.0% during the forecast period
- Based on unit operation, the synthesis segment held the largest revenue share of 39.1% in 2023 driven by technological advancements, efficiency gains, and a shift toward sustainable practices, positioning it for continued expansion in the coming years
- Based on type, generic APIs dominated the market, capturing a substantial revenue share of 10.8% in 2023
- Based on end use, CMO/CDMOs dominated the market, capturing a substantial revenue share of 70.2% in 2023
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Equipment
1.2.2. Unit Operation
1.2.3. Type
1.2.4. End Use
1.2.5. Regional scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Equipment Outlook
2.2.2. Unit Operation
2.2.3. Type
2.2.4. End Use
2.2.5. Regional outlook
2.3. Competitive Insights
CHAPTER 3. CONTINUOUS MANUFACTURING FOR SMALL MOLECULE APIS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rapid growth in the global pharmaceutical industry
3.2.1.2. Growing role of flow chemistry in API manufacturing
3.2.1.3. Growing adoption and improved efficiency & productivity
3.2.1.4. Emergence as a green, sustainable and profitable process technology
3.2.2. Market restraint analysis
3.2.2.1. High R&D investment and capital cost
3.2.2.2. Regulatory compliance and process validation
3.3. Continuous Manufacturing for Small Molecule APIs Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
CHAPTER 4. CONTINUOUS MANUFACTURING FOR SMALL MOLECULE APIS MARKET: EQUIPMENT ESTIMATES & TREND ANALYSIS
4.1. Global Continuous Manufacturing for Small Molecule APIs Market: Equipment Dashboard
4.2. Global Continuous Manufacturing for Small Molecule APIs Market: Equipment Movement Analysis
4.3. Global Continuous Manufacturing for Small Molecule APIs Market by Equipment, Revenue
4.4. Reactors
4.4.1. Reactors market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Crystallizers
4.5.1. Crystallizers market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Filtration Systems
4.6.1. Filtration Systems market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Mixers
4.7.1. Mixers market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Heat Exchangers
4.8.1. Heat Exchangers market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Others (Dryers, etc.)
4.9.1. Others (Dryers, etc.) market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. CONTINUOUS MANUFACTURING FOR SMALL MOLECULE APIS MARKET: UNIT OPERATION ESTIMATES & TREND ANALYSIS
5.1. Global Continuous Manufacturing for Small Molecule APIs Market: Unit Operation Dashboard
5.2. Global Continuous Manufacturing for Small Molecule APIs Market: Unit Operation Movement Analysis
5.3. Global Continuous Manufacturing for Small Molecule APIs Market Estimates and Forecasts, By Unit Operation, Revenue (USD Million)
5.4. Synthesis
5.4.1. Synthesis market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Separation & Purification
5.5.1. Separation & Purification market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Drying
5.6.1. Drying market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. CONTINUOUS MANUFACTURING FOR SMALL MOLECULE APIS MARKET: TYPE ESTIMATES & TREND ANALYSIS
6.1. Global Continuous Manufacturing for Small Molecule APIs Market: Type Dashboard
6.2. Global Continuous Manufacturing for Small Molecule APIs Market: Type Movement Analysis
6.3. Global Continuous Manufacturing for Small Molecule APIs Market Estimates and Forecasts, By Type, Revenue (USD Million)
6.4. Generic APIs
6.4.1. Generic APIs market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Innovative APIs
6.5.1. Innovative APIs market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. CONTINUOUS MANUFACTURING FOR SMALL MOLECULE APIS MARKET: END USE ESTIMATES & TREND ANALYSIS
7.1. Global Continuous Manufacturing for Small Molecule APIs Market: End Use Dashboard
7.2. Global Continuous Manufacturing for Small Molecule APIs Market: End Use Movement Analysis
7.3. Global Continuous Manufacturing for Small Molecule APIs Market Estimates and Forecasts, By End Use, Revenue (USD Million)
7.4. CMOs/CDMOs
7.4.1. CMOs/CDMOs market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Pharmaceutical Companies
7.5.1. Pharmaceutical Companies market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Academic & Research Institutes
7.6.1. Academic & Research Institutes market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. CONTINUOUS MANUFACTURING FOR SMALL MOLECULE APIS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY EQUIPMENT, UNIT OPERATION, TYPE AND END USE
8.1. Regional Dashboard
8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.3. North America
8.3.1. U.S.
8.3.1.1. Key country dynamics
8.3.1.2. Regulatory framework/ reimbursement structure
8.3.1.3. Competitive scenario
8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
8.3.2. Canada
8.3.2.1. Key country dynamics
8.3.2.2. Regulatory framework/ reimbursement structure
8.3.2.3. Competitive scenario
8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
8.3.3. Mexico
8.3.3.1. Key country dynamics
8.3.3.2. Regulatory framework/ reimbursement structure
8.3.3.3. Competitive scenario
8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
8.4. Europe
8.4.1. UK
8.4.1.1. Key country dynamics
8.4.1.2. Regulatory framework/ reimbursement structure
8.4.1.3. Competitive scenario
8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
8.4.2. Germany
8.4.2.1. Key country dynamics
8.4.2.2. Regulatory framework/ reimbursement structure
8.4.2.3. Competitive scenario
8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
8.4.3. France
8.4.3.1. Key country dynamics
8.4.3.2. Regulatory framework/ reimbursement structure
8.4.3.3. Competitive scenario
8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
8.4.4. Italy
8.4.4.1. Key country dynamics
8.4.4.2. Regulatory framework/ reimbursement structure
8.4.4.3. Competitive scenario
8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
8.4.5. Spain
8.4.5.1. Key country dynamics
8.4.5.2. Regulatory framework/ reimbursement structure
8.4.5.3. Competitive scenario
8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
8.4.6. Norway
8.4.6.1. Key country dynamics
8.4.6.2. Regulatory framework/ reimbursement structure
8.4.6.3. Competitive scenario
8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
8.4.7. Sweden
8.4.7.1. Key country dynamics
8.4.7.2. Regulatory framework/ reimbursement structure
8.4.7.3. Competitive scenario
8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
8.4.8. Denmark
8.4.8.1. Key country dynamics
8.4.8.2. Regulatory framework/ reimbursement structure
8.4.8.3. Competitive scenario
8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
8.5.2. China
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
8.5.3. India
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework/ reimbursement structure
8.5.3.3. Competitive scenario
8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
8.5.4. Australia
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework/ reimbursement structure
8.5.4.3. Competitive scenario
8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
8.5.5. South Korea
8.5.5.1. Key country dynamics
8.5.5.2. Regulatory framework/ reimbursement structure
8.5.5.3. Competitive scenario
8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
8.5.6. Thailand
8.5.6.1. Key country dynamics
8.5.6.2. Regulatory framework/ reimbursement structure
8.5.6.3. Competitive scenario
8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
8.6.2. Argentina
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
8.7. MEA
8.7.1. South Africa
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
8.7.2. Saudi Arabia
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
8.7.3. UAE
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
8.7.4. Kuwait
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 9. COMPETITIVE LANDSCAPE
9.1. Company/Competition Categorization
9.2. Vendor Landscape
9.2.1. List of key distributors and channel partners
9.2.2. Key company market share analysis, 2023
9.2.3. Pfizer Inc
9.2.3.1. Company overview
9.2.3.2. Financial performance
9.2.3.3. Equipment benchmarking
9.2.3.4. Strategic initiatives
9.2.4. GSK plc. (GlaxoSmithKline)
9.2.4.1. Company overview
9.2.4.2. Financial performance
9.2.4.3. Equipment benchmarking
9.2.4.4. Strategic initiatives
9.2.5. Vertex Pharmaceuticals Incorporated
9.2.5.1. Company overview
9.2.5.2. Financial performance
9.2.5.3. Equipment benchmarking
9.2.5.4. Strategic initiatives
9.2.6. Janssen (a subsidiary of Johnson & Johnson)
9.2.6.1. Company overview
9.2.6.2. Financial performance
9.2.6.3. Equipment benchmarking
9.2.6.4. Strategic initiatives
9.2.7. Abbvie Inc.
9.2.7.1. Company overview
9.2.7.2. Financial performance
9.2.7.3. Equipment benchmarking
9.2.7.4. Strategic initiatives
9.2.8. Sterling Pharma Solutions
9.2.8.1. Company overview
9.2.8.2. Financial performance
9.2.8.3. Equipment benchmarking
9.2.8.4. Strategic initiatives
9.2.9. Evonik Industries AG
9.2.9.1. Company overview
9.2.9.2. Financial performance
9.2.9.3. Equipment benchmarking
9.2.9.4. Strategic initiatives
9.2.10. Cambrex Corporation
9.2.10.1. Company overview
9.2.10.2. Financial performance
9.2.10.3. Equipment benchmarking
9.2.10.4. Strategic initiatives
9.2.11. Patheon
9.2.11.1. Company overview
9.2.11.2. Financial performance
9.2.11.3. Equipment benchmarking
9.2.11.4. Strategic initiatives
9.2.12. Hovione
9.2.12.1. Company overview
9.2.12.2. Financial performance
9.2.12.3. Equipment benchmarking
9.2.12.4. Strategic initiatives
9.2.13. Lonza
9.2.13.1. Company overview
9.2.13.2. Financial performance
9.2.13.3. Equipment benchmarking
9.2.13.4. Strategic initiatives
9.2.14. Phlow
9.2.14.1. Company overview
9.2.14.2. Financial performance
9.2.14.3. Equipment benchmarking
9.2.14.4. Strategic initiatives
9.2.15. Asymchem
9.2.15.1. Company overview
9.2.15.2. Financial performance
9.2.15.3. Equipment benchmarking
9.2.15.4. Strategic initiatives
9.2.16. GEA Group AG
9.2.16.1. Company overview
9.2.16.2. Financial performance
9.2.16.3. Equipment benchmarking
9.2.16.4. Strategic initiatives
9.2.17. Thermo Fisher Scientific
9.2.17.1. Company overview
9.2.17.2. Financial performance
9.2.17.3. Equipment benchmarking
9.2.17.4. Strategic initiatives
9.2.18. Corning Incorporated
9.2.18.1. Company overview
9.2.18.2. Financial performance
9.2.18.3. Equipment benchmarking
9.2.18.4. Strategic initiatives
9.2.19. Coperion GmbH
9.2.19.1. Company overview
9.2.19.2. Financial performance
9.2.19.3. Equipment benchmarking
9.2.19.4. Strategic initiatives
9.2.20. Continuus Pharmaceuticals
9.2.20.1. Company overview
9.2.20.2. Financial performance
9.2.20.3. Equipment benchmarking
9.2.20.4. Strategic initiatives
9.2.21. Chemtrix
9.2.21.1. Company overview
9.2.21.2. Financial performance
9.2.21.3. Equipment benchmarking
9.2.21.4. Strategic initiatives
9.2.22. Vapourtec Ltd
9.2.22.1. Company overview
9.2.22.2. Financial performance
9.2.22.3. Equipment benchmarking
9.2.22.4. Strategic initiatives
9.2.23. Ehrfeld Mikrotechnik GmbH
9.2.23.1. Company overview
9.2.23.2. Financial performance
9.2.23.3. Equipment benchmarking
9.2.23.4. Strategic initiatives
9.2.24. NiTech Solutions Ltd
9.2.24.1. Company overview
9.2.24.2. Financial performance
9.2.24.3. Equipment benchmarking
9.2.24.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Equipment
1.2.2. Unit Operation
1.2.3. Type
1.2.4. End Use
1.2.5. Regional scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Equipment Outlook
2.2.2. Unit Operation
2.2.3. Type
2.2.4. End Use
2.2.5. Regional outlook
2.3. Competitive Insights
CHAPTER 3. CONTINUOUS MANUFACTURING FOR SMALL MOLECULE APIS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rapid growth in the global pharmaceutical industry
3.2.1.2. Growing role of flow chemistry in API manufacturing
3.2.1.3. Growing adoption and improved efficiency & productivity
3.2.1.4. Emergence as a green, sustainable and profitable process technology
3.2.2. Market restraint analysis
3.2.2.1. High R&D investment and capital cost
3.2.2.2. Regulatory compliance and process validation
3.3. Continuous Manufacturing for Small Molecule APIs Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
CHAPTER 4. CONTINUOUS MANUFACTURING FOR SMALL MOLECULE APIS MARKET: EQUIPMENT ESTIMATES & TREND ANALYSIS
4.1. Global Continuous Manufacturing for Small Molecule APIs Market: Equipment Dashboard
4.2. Global Continuous Manufacturing for Small Molecule APIs Market: Equipment Movement Analysis
4.3. Global Continuous Manufacturing for Small Molecule APIs Market by Equipment, Revenue
4.4. Reactors
4.4.1. Reactors market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Crystallizers
4.5.1. Crystallizers market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Filtration Systems
4.6.1. Filtration Systems market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Mixers
4.7.1. Mixers market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Heat Exchangers
4.8.1. Heat Exchangers market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Others (Dryers, etc.)
4.9.1. Others (Dryers, etc.) market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. CONTINUOUS MANUFACTURING FOR SMALL MOLECULE APIS MARKET: UNIT OPERATION ESTIMATES & TREND ANALYSIS
5.1. Global Continuous Manufacturing for Small Molecule APIs Market: Unit Operation Dashboard
5.2. Global Continuous Manufacturing for Small Molecule APIs Market: Unit Operation Movement Analysis
5.3. Global Continuous Manufacturing for Small Molecule APIs Market Estimates and Forecasts, By Unit Operation, Revenue (USD Million)
5.4. Synthesis
5.4.1. Synthesis market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Separation & Purification
5.5.1. Separation & Purification market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Drying
5.6.1. Drying market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. CONTINUOUS MANUFACTURING FOR SMALL MOLECULE APIS MARKET: TYPE ESTIMATES & TREND ANALYSIS
6.1. Global Continuous Manufacturing for Small Molecule APIs Market: Type Dashboard
6.2. Global Continuous Manufacturing for Small Molecule APIs Market: Type Movement Analysis
6.3. Global Continuous Manufacturing for Small Molecule APIs Market Estimates and Forecasts, By Type, Revenue (USD Million)
6.4. Generic APIs
6.4.1. Generic APIs market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Innovative APIs
6.5.1. Innovative APIs market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. CONTINUOUS MANUFACTURING FOR SMALL MOLECULE APIS MARKET: END USE ESTIMATES & TREND ANALYSIS
7.1. Global Continuous Manufacturing for Small Molecule APIs Market: End Use Dashboard
7.2. Global Continuous Manufacturing for Small Molecule APIs Market: End Use Movement Analysis
7.3. Global Continuous Manufacturing for Small Molecule APIs Market Estimates and Forecasts, By End Use, Revenue (USD Million)
7.4. CMOs/CDMOs
7.4.1. CMOs/CDMOs market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Pharmaceutical Companies
7.5.1. Pharmaceutical Companies market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Academic & Research Institutes
7.6.1. Academic & Research Institutes market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. CONTINUOUS MANUFACTURING FOR SMALL MOLECULE APIS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY EQUIPMENT, UNIT OPERATION, TYPE AND END USE
8.1. Regional Dashboard
8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.3. North America
8.3.1. U.S.
8.3.1.1. Key country dynamics
8.3.1.2. Regulatory framework/ reimbursement structure
8.3.1.3. Competitive scenario
8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
8.3.2. Canada
8.3.2.1. Key country dynamics
8.3.2.2. Regulatory framework/ reimbursement structure
8.3.2.3. Competitive scenario
8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
8.3.3. Mexico
8.3.3.1. Key country dynamics
8.3.3.2. Regulatory framework/ reimbursement structure
8.3.3.3. Competitive scenario
8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
8.4. Europe
8.4.1. UK
8.4.1.1. Key country dynamics
8.4.1.2. Regulatory framework/ reimbursement structure
8.4.1.3. Competitive scenario
8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
8.4.2. Germany
8.4.2.1. Key country dynamics
8.4.2.2. Regulatory framework/ reimbursement structure
8.4.2.3. Competitive scenario
8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
8.4.3. France
8.4.3.1. Key country dynamics
8.4.3.2. Regulatory framework/ reimbursement structure
8.4.3.3. Competitive scenario
8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
8.4.4. Italy
8.4.4.1. Key country dynamics
8.4.4.2. Regulatory framework/ reimbursement structure
8.4.4.3. Competitive scenario
8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
8.4.5. Spain
8.4.5.1. Key country dynamics
8.4.5.2. Regulatory framework/ reimbursement structure
8.4.5.3. Competitive scenario
8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
8.4.6. Norway
8.4.6.1. Key country dynamics
8.4.6.2. Regulatory framework/ reimbursement structure
8.4.6.3. Competitive scenario
8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
8.4.7. Sweden
8.4.7.1. Key country dynamics
8.4.7.2. Regulatory framework/ reimbursement structure
8.4.7.3. Competitive scenario
8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
8.4.8. Denmark
8.4.8.1. Key country dynamics
8.4.8.2. Regulatory framework/ reimbursement structure
8.4.8.3. Competitive scenario
8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
8.5.2. China
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
8.5.3. India
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework/ reimbursement structure
8.5.3.3. Competitive scenario
8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
8.5.4. Australia
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework/ reimbursement structure
8.5.4.3. Competitive scenario
8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
8.5.5. South Korea
8.5.5.1. Key country dynamics
8.5.5.2. Regulatory framework/ reimbursement structure
8.5.5.3. Competitive scenario
8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
8.5.6. Thailand
8.5.6.1. Key country dynamics
8.5.6.2. Regulatory framework/ reimbursement structure
8.5.6.3. Competitive scenario
8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
8.6.2. Argentina
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
8.7. MEA
8.7.1. South Africa
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
8.7.2. Saudi Arabia
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
8.7.3. UAE
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
8.7.4. Kuwait
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 9. COMPETITIVE LANDSCAPE
9.1. Company/Competition Categorization
9.2. Vendor Landscape
9.2.1. List of key distributors and channel partners
9.2.2. Key company market share analysis, 2023
9.2.3. Pfizer Inc
9.2.3.1. Company overview
9.2.3.2. Financial performance
9.2.3.3. Equipment benchmarking
9.2.3.4. Strategic initiatives
9.2.4. GSK plc. (GlaxoSmithKline)
9.2.4.1. Company overview
9.2.4.2. Financial performance
9.2.4.3. Equipment benchmarking
9.2.4.4. Strategic initiatives
9.2.5. Vertex Pharmaceuticals Incorporated
9.2.5.1. Company overview
9.2.5.2. Financial performance
9.2.5.3. Equipment benchmarking
9.2.5.4. Strategic initiatives
9.2.6. Janssen (a subsidiary of Johnson & Johnson)
9.2.6.1. Company overview
9.2.6.2. Financial performance
9.2.6.3. Equipment benchmarking
9.2.6.4. Strategic initiatives
9.2.7. Abbvie Inc.
9.2.7.1. Company overview
9.2.7.2. Financial performance
9.2.7.3. Equipment benchmarking
9.2.7.4. Strategic initiatives
9.2.8. Sterling Pharma Solutions
9.2.8.1. Company overview
9.2.8.2. Financial performance
9.2.8.3. Equipment benchmarking
9.2.8.4. Strategic initiatives
9.2.9. Evonik Industries AG
9.2.9.1. Company overview
9.2.9.2. Financial performance
9.2.9.3. Equipment benchmarking
9.2.9.4. Strategic initiatives
9.2.10. Cambrex Corporation
9.2.10.1. Company overview
9.2.10.2. Financial performance
9.2.10.3. Equipment benchmarking
9.2.10.4. Strategic initiatives
9.2.11. Patheon
9.2.11.1. Company overview
9.2.11.2. Financial performance
9.2.11.3. Equipment benchmarking
9.2.11.4. Strategic initiatives
9.2.12. Hovione
9.2.12.1. Company overview
9.2.12.2. Financial performance
9.2.12.3. Equipment benchmarking
9.2.12.4. Strategic initiatives
9.2.13. Lonza
9.2.13.1. Company overview
9.2.13.2. Financial performance
9.2.13.3. Equipment benchmarking
9.2.13.4. Strategic initiatives
9.2.14. Phlow
9.2.14.1. Company overview
9.2.14.2. Financial performance
9.2.14.3. Equipment benchmarking
9.2.14.4. Strategic initiatives
9.2.15. Asymchem
9.2.15.1. Company overview
9.2.15.2. Financial performance
9.2.15.3. Equipment benchmarking
9.2.15.4. Strategic initiatives
9.2.16. GEA Group AG
9.2.16.1. Company overview
9.2.16.2. Financial performance
9.2.16.3. Equipment benchmarking
9.2.16.4. Strategic initiatives
9.2.17. Thermo Fisher Scientific
9.2.17.1. Company overview
9.2.17.2. Financial performance
9.2.17.3. Equipment benchmarking
9.2.17.4. Strategic initiatives
9.2.18. Corning Incorporated
9.2.18.1. Company overview
9.2.18.2. Financial performance
9.2.18.3. Equipment benchmarking
9.2.18.4. Strategic initiatives
9.2.19. Coperion GmbH
9.2.19.1. Company overview
9.2.19.2. Financial performance
9.2.19.3. Equipment benchmarking
9.2.19.4. Strategic initiatives
9.2.20. Continuus Pharmaceuticals
9.2.20.1. Company overview
9.2.20.2. Financial performance
9.2.20.3. Equipment benchmarking
9.2.20.4. Strategic initiatives
9.2.21. Chemtrix
9.2.21.1. Company overview
9.2.21.2. Financial performance
9.2.21.3. Equipment benchmarking
9.2.21.4. Strategic initiatives
9.2.22. Vapourtec Ltd
9.2.22.1. Company overview
9.2.22.2. Financial performance
9.2.22.3. Equipment benchmarking
9.2.22.4. Strategic initiatives
9.2.23. Ehrfeld Mikrotechnik GmbH
9.2.23.1. Company overview
9.2.23.2. Financial performance
9.2.23.3. Equipment benchmarking
9.2.23.4. Strategic initiatives
9.2.24. NiTech Solutions Ltd
9.2.24.1. Company overview
9.2.24.2. Financial performance
9.2.24.3. Equipment benchmarking
9.2.24.4. Strategic initiatives
